{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:49:01Z","timestamp":1790808541639,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["Biomarkers Research Initiative"],"award-info":[{"award-number":["Biomarkers Research Initiative"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00702-025-03007-w","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:13:15Z","timestamp":1762143195000},"page":"1397-1406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum L-ornithine-derived polyamines as indicators of Parkinson disease progression"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4976-4445","authenticated-orcid":false,"given":"Peter A.","family":"LeWitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Auinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Parkinson Study Group DATATOP Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"5","key":"3007_CR15","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1074\/jbc.M208249200","volume":"278","author":"T Antony","year":"2003","unstructured":"Antony T et al (2003) Cellular polyamines promote the aggregation of alpha-synuclein. J Biol Chem 278(5):3235\u20133240","journal-title":"J Biol Chem"},{"issue":"1","key":"3007_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/nu12010197","volume":"12","author":"AK Bekebrede","year":"2020","unstructured":"Bekebrede AK et al (2020) The molecular and physiological effects of protein-derived polyamines in the intestine. Nutrients 12(1):197. https:\/\/doi.org\/10.3390\/nu12010197","journal-title":"Nutrients"},{"key":"3007_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jchromb.2018.02.015","volume":"1081\u20131082","author":"L Betancourt","year":"2018","unstructured":"Betancourt L et al (2018) Micellar electrokinetic chromatography with laser induced fluorescence detection shows increase of putrescine in erythrocytes of Parkinson\u2019s disease patients. J Chromatogr B Analyt Technol Biomed Life Sci 1081\u20131082:51","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"3007_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/JPD-2011-11035","volume":"1","author":"PO Buck","year":"2011","unstructured":"Buck PO et al (2011) Examination of the UPDRS bradykinesia subscale: equivalence, reliability, and validity. J Parkinson Dis 1(3):253\u2013258","journal-title":"J Parkinson Dis"},{"issue":"24","key":"3007_CR44","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.4161\/15384101.2014.973309","volume":"13","author":"S B\u00fcttner","year":"2014","unstructured":"B\u00fcttner S et al (2014) Spermidine protects against \u03b1-synuclein neurotoxicity. Cell Cycle 13(24):3903\u20133908","journal-title":"Cell Cycle"},{"issue":"1","key":"3007_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nan.12298","volume":"42","author":"K Del Tredici","year":"2016","unstructured":"Del Tredici K, Braak H (2016) Review: sporadic Parkinson\u2019s disease: development and distribution of \u03b1-synuclein pathology. Neuropathol Appl Neurobiol 42(1):33\u201350","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3007_CR31","unstructured":"Fahn S, Elton RL, UPDRS Development Committee (1987). Unified Parkinson\u2019s disease rating. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson\u2019s disease, vol 2. MacMillan Healthcare Information; :153\u2013163,293\u2013304"},{"issue":"8","key":"3007_CR39","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/mds.25776","volume":"29","author":"E Gelpi","year":"2014","unstructured":"Gelpi E et al (2014) Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 29(8):1010\u20131018","journal-title":"Mov Disord"},{"issue":"2","key":"3007_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1006\/exnr.2002.7952","volume":"177","author":"C Gomes-Trollin","year":"2002","unstructured":"Gomes-Trollin C et al (2002) Increased red blood cell polyamines in ALS and Parkinson\u2019s disease. Exptl Neurol 177(2):515\u2013520","journal-title":"Exptl Neurol"},{"issue":"35","key":"3007_CR16","doi-asserted-by":"publisher","first-page":"11147","DOI":"10.1021\/jp801175w","volume":"112","author":"M Grabenauer","year":"2008","unstructured":"Grabenauer M et al (2008) Spermine binding to Parkinson\u2019s protein \u03b1-synuclein and its disease-related A30P and A53T mutants. J Phys Chem B 112(35):11147\u201311154","journal-title":"J Phys Chem B"},{"issue":"Suppl 2","key":"3007_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000518147","volume":"77","author":"M Hirayama","year":"2021","unstructured":"Hirayama M, Ohno K (2021) Parkinson\u2019s disease and gut microbiota. Ann Nutr Metab 77(Suppl 2):28\u201335. https:\/\/doi.org\/10.1159\/000518147","journal-title":"Ann Nutr Metab"},{"issue":"10","key":"3007_CR4","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00726-021-03073-w","volume":"53","author":"K Igarashi","year":"2021","unstructured":"Igarashi K, Kashiwagi K (2021) Functional roles of polyamines and their metabolite acrolein in eukaryotic cells. Amino Acids 53(10):1473\u20131492","journal-title":"Amino Acids"},{"issue":"10","key":"3007_CR33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J et al (1990) Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort. Neurology 40(10):1529\u20131534","journal-title":"Neurology"},{"issue":"2","key":"3007_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/niom12020329","volume":"12","author":"EH Kwon","year":"2022","unstructured":"Kwon EH et al (2022) Update on CSF biomarkers in Parkinson\u2019s disease. Biomolecules 12(2):329. https:\/\/doi.org\/10.3390\/niom12020329","journal-title":"Biomolecules"},{"issue":"39","key":"3007_CR18","doi-asserted-by":"publisher","first-page":"16970","DOI":"10.1073\/pnas.1011751107","volume":"USA107","author":"NM Lewandowski","year":"2010","unstructured":"Lewandowski NM et al (2010) Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci USA107(39):16970\u201316975","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"3007_CR42","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1212\/WNL.42.11.2111","volume":"42","author":"P LeWitt","year":"1992","unstructured":"LeWitt P et al (1992) Markers of dopamine metabolism in Parkinson\u2019s disease. Neurology 42(11):2111\u20132117","journal-title":"Neurology"},{"issue":"2","key":"3007_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.870120208","volume":"12","author":"P LeWitt","year":"1997","unstructured":"LeWitt P, Oakes D, Cui LU, Parkinson Study Group (1997) The need for levodopa as an end point of Parkinson\u2019s disease progression in a clinical trial of selegiline and a-tocopherol. Mov Disord 12(2):183\u2013189","journal-title":"Mov Disord"},{"key":"3007_CR21","doi-asserted-by":"publisher","first-page":"105962","DOI":"10.1016\/j.nbd.2022.105962","volume":"177","author":"PA LeWitt","year":"2023","unstructured":"LeWitt PA, Li J, Wu K-H, Lu M (2023) Diagnostic metabolomic profiling of Parkinson disease biospecimens. Neurobiol Dis 177:105962","journal-title":"Neurobiol Dis"},{"issue":"21","key":"3007_CR3","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1016\/j.jmb.2015.06.020","volume":"427","author":"L Miller-Fleming","year":"2015","unstructured":"Miller-Fleming L et al (2015) Remaining mysteries of molecular biology: the role of polyamines in the cell. J Mol Biol 427(21):3389\u20133406","journal-title":"J Mol Biol"},{"issue":"2","key":"3007_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clnu.2004.11.001","volume":"24","author":"C Moinard","year":"2005","unstructured":"Moinard C, Cyniber L, de Bandt JP (2005) Polyamines: metabolism and implications in human diseases. Clin Nutr 24(2):184\u2013197","journal-title":"Clin Nutr"},{"issue":"10423","key":"3007_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (2024) The pathogenesis of Parkinson\u2019s disease. Lancet 403(10423):293\u2013304","journal-title":"Lancet"},{"issue":"19\u201320","key":"3007_CR25","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.cca.2010.05.034","volume":"411","author":"M-J Paik","year":"2010","unstructured":"Paik M-J et al (2010) Polyamine patterns in the cerebrospinal fluid of patients with Parkinson\u2019s disease and multiple system atrophy. Clin Chim Acta 411(19\u201320):1532\u20131535","journal-title":"Clin Chim Acta"},{"issue":"6","key":"3007_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/mds.26243","volume":"30","author":"J-S Park","year":"2015","unstructured":"Park J-S, Blair NF, Sue CM (2015) The role of ATP13A2 in Parkinson\u2019s disease: clinical phenotypes and molecular mechanisms. Mov Disord 30(6):770\u2013779","journal-title":"Mov Disord"},{"issue":"10","key":"3007_CR28","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","volume":"46","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group (1989a) DATATOP: a multicenter controlled clinical trial in early Parkinson\u2019s disease. Arch Neurol 46(10):1052\u20131060","journal-title":"Arch Neurol"},{"issue":"20","key":"3007_CR29","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","volume":"321","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group (1989b) Deprenyl forestalls disability in early Parkinson\u2019s disease: a controlled clinical trial. N Engl J Med 321(20):1364\u20131371","journal-title":"N Engl J Med"},{"issue":"3","key":"3007_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1056\/NEJM199301213280305","volume":"328","author":"Parkinson Study Group","year":"1993","unstructured":"Parkinson Study Group (1993) Effect of tocopherol and deprenyl on the progression of disability in early Parkinson\u2019s disease. N Engl J Med 328(3):176\u201318","journal-title":"N Engl J Med"},{"issue":"6","key":"3007_CR19","doi-asserted-by":"publisher","first-page":"E995","DOI":"10.1152\/ajpendo.90217.2008","volume":"294","author":"AE Pegg","year":"2008","unstructured":"Pegg AE (2008) Spermidine\/spermine-N(1)-acetyltransferase: a key metabolic regulator. Am J Physiol Endocrinol Metab 294(6):E995\u20131010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"3007_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/iub.230","volume":"61","author":"AE Pegg","year":"2009","unstructured":"Pegg AE (2009) Mammalian polyamine metabolism and function. IUBMB Life 61(9):880\u2013894","journal-title":"IUBMB Life"},{"issue":"1","key":"3007_CR22","doi-asserted-by":"publisher","first-page":"10036","DOI":"10.1038\/s41598-024-60872-3","volume":"14","author":"K-W Peng","year":"2024","unstructured":"Peng K-W et al (2024) Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson\u2019s disease biomarker panel. Sci Rep 14(1):10036. https:\/\/doi.org\/10.1038\/s41598-024-60872-3","journal-title":"Sci Rep"},{"issue":"4","key":"3007_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/ana.410190409","volume":"19","author":"PC Phillips","year":"1986","unstructured":"Phillips PC, Kremzner LT, DeVivo DC (1986) Cerebrospinal fluid polyamines: biochemical markers of malignant childhood brain tumors. Ann Neurol 19(4):360\u2013364","journal-title":"Ann Neurol"},{"key":"3007_CR45","doi-asserted-by":"publisher","unstructured":"Ranxhi B et al (2025) Regulation of polyamine interconversion enzymes affects \u03b1-synuclein levels and toxicity in a Drosophila model of Parkinson\u2019s disease. NPJ npg Parkinson\u2019s Dis. 11:231. https:\/\/doi.org\/10.1038\/s41531-025-01087-9","DOI":"10.1038\/s41531-025-01087-9"},{"key":"3007_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1146\/annurev.pa.35.040195.002335","volume":"35","author":"DM Rock","year":"1995","unstructured":"Rock DM, Macdonald RL (1995) Polyamine regulation of N-methyl-D-aspartate receptor channels. Annu Rev Pharmacol Toxicol 35:463\u2013482","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10","key":"3007_CR26","doi-asserted-by":"publisher","first-page":"e77629","DOI":"10.1371\/journal.pone.0077629","volume":"8","author":"JR Roede","year":"2013","unstructured":"Roede JR et al (2013) Serum metabolomics on slow vs. rapid motor progression Parkinson\u2019s disease: a pilot study. PLoS One 8(10):e77629. https:\/\/doi.org\/10.1371\/journal.pone.0077629","journal-title":"PLoS One"},{"issue":"2","key":"3007_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ana.25516","volume":"86","author":"S Saiki","year":"2019","unstructured":"Saiki S et al (2019) A metabolic profile of polyamines in Parkinson\u2019s disease: a promising biomarker. Ann Neurol 86(2):251\u2013263","journal-title":"Ann Neurol"},{"issue":"1","key":"3007_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10048-010-0259-0","volume":"12","author":"L Santoro","year":"2011","unstructured":"Santoro L, Breedveld GJ, Manganelli F et al (2011) Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 12(1):33\u201339","journal-title":"Neurogenetics"},{"key":"3007_CR11","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/ijms22052689","volume":"22","author":"J Si","year":"2021","unstructured":"Si J et al (2021) ATP13A2 regulates cellular \u03b1-synuclein multimerization, membrane association, and externalization. Int J Mol Sci 22:2689. https:\/\/doi.org\/10.3390\/ijms22052689","journal-title":"Int J Mol Sci"},{"key":"3007_CR43","doi-asserted-by":"publisher","first-page":"736978","DOI":"10.3389\/fmed.2021.736978","volume":"8","author":"E Srinivasan","year":"2021","unstructured":"Srinivasan E et al (2021) Alpha-synuclein aggregation in Parkinson\u2019s disease. Front Med (Lausanne) 8:736978. https:\/\/doi.org\/10.3389\/fmed.2021.736978","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"3007_CR37","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00702-022-02498-1","volume":"129","author":"L T\u00f6nges","year":"2022","unstructured":"T\u00f6nges L et al (2022) Blood-based biomarker in Parkinson\u2019s disease: potential for future applications in clinical research and practice. J Neural Transm (Vienna) 129(9):1201\u20131217","journal-title":"J Neural Transm (Vienna)"},{"issue":"7795","key":"3007_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41586-020-1968-7","volume":"578","author":"S van Veen","year":"2020","unstructured":"van Veen S et al (2020) ATP13A2 deficiency disrupts lysosomal polyamine export. Nature 578(7795):419\u2013424","journal-title":"Nature"},{"issue":"49","key":"3007_CR10","doi-asserted-by":"publisher","first-page":"31198","DOI":"10.1073\/pnas.1922342117","volume":"117","author":"S Vrijsen","year":"2020","unstructured":"Vrijsen S et al (2020) ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress. Proc Natl Acad Sci USA 117(49):31198\u201331207","journal-title":"Proc Natl Acad Sci USA"},{"key":"3007_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev-biochem-071322-021330","volume":"92","author":"S Vrijsen","year":"2023","unstructured":"Vrijsen S et al (2023) Polyamines in Parkinson disease: balancing between neurotoxicity and neuroprotection. Ann Rev Biochem 92:435\u2013464","journal-title":"Ann Rev Biochem"},{"issue":"1","key":"3007_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0898-6568(96)00089-7","volume":"9","author":"K Williams","year":"1997","unstructured":"Williams K (1997) Modulation and block of ion channels: a new biology of polyamines. Cell Signal 9(1):1\u201313","journal-title":"Cell Signal"},{"issue":"4","key":"3007_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1212\/WNL.35.4.522","volume":"35","author":"WJ Zetusky","year":"1985","unstructured":"Zetusky WJ, Jankovic J, Pirozzolo FJ (1985) The heterogeneity of Parkinson\u2019s disease: clinical and prognostic implications. Neurology 35(4):522\u2013526","journal-title":"Neurology"},{"issue":"1","key":"3007_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40035-023-00392-8","volume":"12","author":"X Zhang","year":"2023","unstructured":"Zhang X, Tang B, Guo J (2023) Parkinson\u2019s disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Transl Neurodegener 12(1):59. https:\/\/doi.org\/10.1186\/s40035-023-00392-8","journal-title":"Transl Neurodegener"},{"key":"3007_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0304-3940(96)12478-2","volume":"207","author":"M Zoli","year":"1996","unstructured":"Zoli M, Pedrazzi P, Agnati LF (1996) Regional and cellular distribution of spermidine\/spermine N1-acetyltransferase (SSAT) mRNA in the rat central nervous system. Neurosci Lett 207:13\u201316","journal-title":"Neurosci Lett"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03007-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:06:57Z","timestamp":1785600417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03007-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3007"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03007-w","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to their study participation in the DATATOP study at each clinical site, all enrolled subjects had reviewed the study plan with investigators and signed an IRB-approved informed consent form. The consent form authorized the use of clinical information and biospecimens in the current study and in future biomarker research (such as in the current study). The DATATOP study was conducted according to the Declaration of Helsinki principles.","order":2,"name":"Ethics","label":"Study approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}